TPM1 and prostate carcinoma: In prostate cancer, osteosarcoma, urinary tract epithelial cancer and pituitary tumor cells, MEG3 could directly bind to miR-361-5p, miR-96, and miR-376B-3p, leading to the promotion of forkhead box M1 (FoxM1) and tropomyosin 1 (TPM1) expression while repressing oncogene high mobility group AT-hook 2 (HMGA2) expression.